

28 February 2022

Financial Services | Banks

AMMB (AMM MK)

Buy (Maintained)

Biting The Bullet On O&G Exposures; Keep BUY

Target Price (Return): MYR4.00 (16.6%)
 Price (Market Cap): MYR3.43 (USD2,703m)
 ESG score: 2.90 (out of 4)
 Avg Daily Turnover (MYR/USD) 9.34m/2.23m

- **Stay BUY, with a higher MYR4.00 TP from MYR3.90, 17% upside.** AMMB's 9MFY22 (Mar) results were above expectations, helped by a MYR234.5m tax credit. Management is clearing the deck on oil & gas (O&G) exposures which push credit cost above guidance. Still, net profit target of MYR1.4bn is within reach while capital rebuild remains on track. The loan book clean-up, improving prospects for resumption of dividend payouts, and undemanding valuation, we believe, are all catalysts for share price re-rating.
- **9MFY22 beat on tax credit.** Net profit of MYR403m (+26% QoQ) in 3QFY22, took 9MFY22 earnings to MYR1,111m (+28% YoY) – which was 87%/92% of our/Street's FY22F. The variance came from the recognition of MYR234.5m in tax credit (related to the MYR2.83bn settlement - see details on page 4) that offset MYR73.5m in Cukai Makmur and sharply higher provisions in 3QFY22. PIOP (+11% YoY) was within our expectations. 9MFY22 ROAE rose to 9.2% (FY21: 5% core), while CET-1 ticked up to 11.9% (target: 12%).
- **Key trends in 3QFY22.** PIOP rose 8% QoQ on strong rise in NII and well controlled opex growth. NII jumped 8% QoQ as loan growth momentum gained pace to 4% YTD while NIM +6bps on unwinding of modification loss. Non-IL dipped 1% QoQ on lower investments gains that negated the 9% rise in core fees. With opex growth a lower 3%, CIR improved to 44.7% (2QFY22: 45.8%). Impairments spiked 94% QoQ to MYR337m largely due to MYR280m provisions for an O&G exposure and MYR45m in additional overlays. Loan credit cost rose to 72bps in 9MFY22 from 61% in 1HFY22.
- **Asset quality.** Management expects to impair a second O&G exposure of MYR600m in 4QFY22 with additional provisions to fully provide for the NPL. The bank's loans under repayment assistance (LURA) eased to MYR17.8bn (15% of total loans) on 18 Feb 2022 from MYR33.7bn (29% of total loans) in Nov 2021. The clean-up of its loans book led to lower GIL ratio of 1.35% and higher LLC of 164%. Still, FY22F credit cost guidance is raised to 72bps from 60bps due to impairment of O&G exposures, while GIL ratio would rise c.40bps.
- **Other highlights.** With the pick-up in economic activities, loan growth target of 5% is now within reach after the soft 1HFY22. NIM would likely dip in 4QFY22 as unwinding of modification loss tapers and NPLs rise. Opex will be higher QoQ, lifting CIR to c.45%. Management reiterated that decision on dividend will only be made at end-FY22. We have not factored in any dividend payout for FY22F pending greater certainty on this matter.
- **Earnings forecasts and TP.** Our FY22F net profit is higher by 10% as we factor in the tax credit, which more than offset higher provisions for the O&G exposures (Figure 3). Our TP is a tad higher at MYR4.00 (from MYR3.90) as intrinsic value is tweaked to MYR4.08 (from MYR3.94) with a 2% ESG discount based on our in-house ESG methodology (Figure 4). The intrinsic value is based on GGM-derived P/BV of 0.69x.

Analysts

Fiona Leong
 +603 9280 8886
fiona.leong@rhbgroupp.com




Eddy Do Wey Qing
 +603 9280 8856
wey.qing.do@rhbgroupp.com



Share Performance (%)

	YTD	1m	3m	6m	12m
Absolute	8.2	2.4	6.2	14.3	6.2
Relative	6.7	(3.1)	1.3	12.9	5.6
52-wk Price low/high (MYR)	2.80 – 3.60				



Source: Bloomberg

Forecasts and Valuation	Mar-20	Mar-21	Mar-22F	Mar-23F	Mar-24F
Reported net profit (MYRm)	1,341	(3,826)	1,404	1,662	1,808
Net profit growth (%)	(10.9)	(385.4)	-	18.4	8.8
Recurring net profit (MYRm)	1,341	962	1,404	1,662	1,808
Recurring EPS (MYR)	0.45	0.32	0.43	0.50	0.55
BVPS (MYR)	6.16	4.86	5.58	6.06	6.66
DPS (MYR)	0.13	na	na	0.19	0.21
Recurring P/E (x)	7.68	10.72	8.05	6.80	6.25
P/B (x)	0.56	0.71	0.62	0.57	0.51
Dividend Yield (%)	3.9	na	na	5.4	6.0
Return on average equity (%)	7.4	(23.0)	8.9	9.5	9.4

Source: Company data, RHB

Overall ESG Score: 2.90 (out of 4)

E: GOOD

AMMB has established greenhouse gas accounting and reporting practice guide to better understand and track our carbon emissions. It launched the "No Single-Use Plastic Program" to eliminate the use of single-use plastics cutlery at the premises.

S: GOOD

AMMB practices financial inclusion and responsible lending policies that promotes accessibility of financial services and products to the underserved segments. Key initiatives in include AmBank BizClub that provides education, training, development, social media exposure and networking opportunities that help SMEs scale their business.

G: GOOD

AMMB's board comprises eight directors (five independent directors). All directors are assessed annually via the Board Effectiveness Evaluation exercise. The Independent Directors assessed in the financial year under review, satisfied the independence criteria specified under the Bank Negara Malaysia (BNM) Policy Documents on Corporate Governance and the MMLR of Bursa Securities and therefore maintained their independent status.

Financial Exhibits

Asia	Financial summary (MYR)	Mar-20	Mar-21	Mar-22F	Mar-23F	Mar-24F
Malaysia	EPS	0.45	(1.27)	0.43	0.50	0.55
Financial Services	Recurring EPS	0.45	0.32	0.43	0.50	0.55
AMMB	DPS	0.13	-	-	0.19	0.21
AMM MK	BVPS	6.16	4.86	5.58	6.06	6.66
Buy						
Valuation basis	Valuation metrics	Mar-20	Mar-21	Mar-22F	Mar-23F	Mar-24F
GGM-derived intrinsic value with an ESG overlay. Key GGM assumptions are:	Recurring P/E (x)	7.68	10.72	8.05	6.80	6.25
i) COE of 11.5%;	P/B (x)	0.6	0.7	0.6	0.6	0.5
ii) ROE assumption of 9%; and	Dividend Yield (%)	3.9	na	na	5.4	6.0
iii) 3.5% long-term growth.						
Key drivers	Income statement (MYRm)	Mar-20	Mar-21	Mar-22F	Mar-23F	Mar-24F
Our FY22 earnings are most sensitive to changes in:	Interest income	6,950	5,902	5,953	6,355	6,716
i) NIM;	Interest expense	(4,176)	(2,966)	(2,619)	(2,812)	(2,993)
ii) Loan impairment allowances;	Net interest income	2,774	2,935	3,333	3,542	3,723
iii) Non-interest income.	Non interest income	1,456	1,573	1,422	1,507	1,595
	Total operating income	4,230	4,509	4,755	5,049	5,318
	Overheads	(2,108)	(2,132)	(2,155)	(2,270)	(2,377)
	Pre-provision operating profit	2,122	2,376	2,600	2,779	2,941
	Loan impairment allowances	(290)	(1,145)	(836)	(543)	(504)
	Other impairment allowances	(47)	(4,758)	(25)	(18)	(12)
	Income from associates	(3)	44	40	43	46
	Pre-tax profit	1,783	(3,483)	1,779	2,261	2,471
	Taxation	(330)	(229)	(295)	(509)	(568)
	Minority interests	(112)	(114)	(81)	(90)	(95)
	Reported net profit	1,341	(3,826)	1,404	1,662	1,808
	Recurring net profit	1,341	962	1,404	1,662	1,808
Company Profile	Profitability ratios	Mar-20	Mar-21	Mar-22F	Mar-23F	Mar-24F
AMMB Holdings provides a wide range of financial products and services. Its business divisions covers retail banking, business banking, transaction banking, corporate and institutional banking, investment banking including funds management and stockbroking, markets, general insurance, life assurance and Takaful. These business divisions offer both Conventional and Islamic financial services.	Return on average assets (%)	0.8	(2.3)	0.8	0.9	0.9
	Return on average equity (%)	7.4	(23.0)	8.9	9.5	9.4
	Return on IEAs (%)	4.5	3.6	3.5	3.5	3.5
	Cost of funds (%)	3.0	2.1	1.7	1.7	1.8
	Net interest spread (%)	1.4	1.5	1.7	1.7	1.7
	Net interest margin (%)	1.8	1.8	1.9	1.9	1.9
	Non-interest income / total income (%)	34.4	34.9	29.9	29.8	30.0
	Cost to income ratio (%)	49.8	47.3	45.3	45.0	44.7
	Credit cost (bps)	27.7	103.2	71.2	44.0	38.8
	Balance sheet (MYRm)	Mar-20	Mar-21	Mar-22F	Mar-23F	Mar-24F
	Total gross loans	107,219	114,759	120,194	126,615	132,946
	Other interest earning assets	54,909	51,744	57,690	60,295	63,523
	Total gross IEAs	162,128	166,503	177,884	186,910	196,469
	Total provisions	(1,268)	(2,280)	(2,567)	(2,859)	(3,139)
	Net loans to customers	105,951	112,478	117,626	123,756	129,807
	Total net IEAs	160,860	164,223	175,316	184,051	193,330
	Total non-IEAs	8,343	5,956	6,358	6,427	6,497
	Total assets	169,203	170,178	181,674	190,478	199,827
	Customer deposits	113,175	120,638	127,403	134,552	141,298
	Other interest-bearing liabilities	29,953	25,559	30,363	30,525	31,375
	Total IBLs	143,128	146,197	157,766	165,077	172,673
	Total non-IBLs	6,515	8,390	6,070	6,006	5,954
	Total liabilities	149,643	154,588	163,836	171,083	178,627
	Share capital	5,852	5,952	6,776	6,776	6,776
	Shareholders' equity	18,581	14,641	16,808	18,273	20,079
	Minority interests	979	950	1,031	1,121	1,121
	Asset quality and capital	Mar-20	Mar-21	Mar-22F	Mar-23F	Mar-24F
	Reported NPLs / gross cust loans (%)	1.7	1.5	1.8	1.6	1.5
	Total provisions / reported NPLs (%)	68.4	128.8	121.4	141.1	156.9
	CET-1 ratio (%)	12.4	11.3	12.8	13.0	14.0
	Tier-1 ratio (%)	12.6	11.3	12.8	13.0	14.0
	Total capital ratio (%)	16.0	14.5	15.6	15.6	16.5

Source: Company data, RHB

Results At a Glance

Figure 1: Summary of AMMB's 3QFY22 and 9MFY22 results

FYE Mar (MYRm)	3QFY21	2QFY22	3QFY22	QoQ (%)	YoY (%)	9MFY21	9MFY22	YoY (%)	Comments – 9MFY22 vs 9MFY21
NII (+ Islamic Banking)	848	799	867	8	2	2,247	2,515	12	Up YoY on NIM recovery and pick-up in loan growth.
NIM (%) - reported	1.96	2.03	2.09			1.85	2.06		NIM recovered 21bps YoY on lower funding costs and unwinding of modification loss of MYR115m.
Non-II	313	316	313	(1)	0	1,139	992	(13)	Down YoY mainly on lower treasury and trading gains (-59% YoY), and insurance income (-23% YoY).
Non-II/Total income (%)	26.9	28.4	26.5			33.6	28.3		
Operating income	1,160	1,115	1,180	6	2	3,386	3,507	4	
Overhead expenses	(545)	(514)	(529)	3	(3)	(1,608)	(1,537)	(4)	Lower YoY with spending tightly managed.
CIR (%)	47.0	46.0	44.8			47.5	43.8		Curtailment in opex led in positive jaws.
PIOP	615	602	651	8	6	1,779	1,970	11	
Impairments on financial assets	(2)	(4)	(5)	45	>100	10	(19)	>100	
Impairment losses on loans	(260)	(170)	(332)	95	28	(655)	(696)	6	The QoQ spike came mainly from MYR280m provisions for a MYR300m O&G exposure and MYR45m in additional management overlays. Total overlay reserves carried forward stood at MYR945.2m at end-Dec 21.
Annualised credit cost (bps)	93	59	113			80	79		
Operating profit	353	428	314	(27)	(11)	1,134	1,255	11	
Associates	16	6	3	(44)	(80)	37	35	(6)	
Pretax profit	369	433	317	(27)	(14)	1,171	1,290	10	
Tax	(86)	(95)	100	>100	>100	(214)	(113)	(47)	
Effective tax rate	23.2	22.0	(31.5)			18.2	8.8		
Minorities	(19)	(17)	(13)	(21)	(30)	(91)	(66)	(28)	
Net profit	264	321	403	26	53	866	1,111	28	9MFY22 earnings was 87%/92% of our/Street's FY22F net profit
Other key data and ratio									
Gross loans	111,898	115,553	119,307	3.2	6.6				Loan growth picked up to 4% YTD or an annualised 5.2% at end-Dec 21.
Customer deposits	119,041	115,871	124,710	7.6	4.8				CASA deposits grew 4.6% YTD or an annualised 6.2% at end-Dec 21.
Gross impaired loans	1,936	1,668	1,608	(3.6)	(16.9)				Down QoQ mainly due to higher write-offs and recoveries.
Total assets	172,515	163,568	179,561	9.8	4.1				
Shareholders' funds	19,575	16,125	16,466	2.1	(15.9)				
ROAA (%)	0.65	0.82	0.99			0.70	0.89		
ROAE (%)	5.4	8.0	9.9			6.1	9.5		
LDR (%)	92.3	97.4	93.5						
GIL ratio (%)	1.73	1.44	1.35						
Loan loss coverage (%)	103.4	159.0	164.4						

Source: Company data, RHB

Management updates and guidance

Update on O&G exposure. In 3QFY22, management continued to clean up the bank's O&G exposures. It impaired an O&G account worth c.MYR300m with provisions of MYR280m booked. This was a key factor that led to the 94% rise in loan provision charges to MYR337m (includes MYR45m in additional management overlays). Management expects to impair a second O&G exposure of MYR600m in 4QFY22, which has 60% provision coverage currently. Provisions for the balance 40% will likely also be booked in 4QFY22.

Tax credit. AMMB's effective tax rate stood at a low 8.8% in 9MFY22 (1HFY22: 21.9%) as it wrote-back MYR234.5m tax paid related to the MYR2.83bn settlement paid in FY21. Following consultations, management has filed for tax credits worth MYR667m arising from the settlement. If approved, AMMB will recognise the balance of MYR433m in subsequent years. Recall that in Mar 2020, AMMB has reached an agreement with the Ministry of Finance Malaysia for a sum of MYR2.83bn as the final settlement in relation to the overall transactions by 1Malaysia Development Berhad (1MDB).

Figure 2: AMMB – management guidance and financial targets

	Achieved in 9MFY22	FY22 targets	Comments
PATAMI	MYR1,111m	MYR1.40bn	Although 4QFY22 net profit would be lower than the quarterly run-rate of MYR350m due to provisions to be taken for the second O&G exposure, the target remains achievable helped by the MYR234m tax credit.
Loan growth	+4% YTD (5.3% annualised)	5.0% YoY	With the healthy 3.2% QoQ pick-up in 3QFY22 loan growth expected to be sustained in 4QFY22, management believes the loan growth target is achievable.
NIM	+21bps YTD to 2.06%	2.04-2.05% (revised from 2.08%)	Management fine-tuned its NIM expectations to 2.04-2.05%. Against the 2.06% achieved for 9MFY22, the revised guidance point to NIM pressures in 4QFY22.
CIR	43.4%	45%	Management reiterated its CIR guidance, as opex is expected to be sequentially higher in 4QFY22 due to investments for growth and digital capabilities.
Credit cost	72bps	72bps (revised from 60bps)	Management raised credit cost guidance to 72bps, from 60bps, taking into account provisions for the bank's O&G exposures.
CET-1	11.9%	12%	With capital rebuild progressing well, we believe the bank would review the decision on dividend at end-FY22.

Source: Company data, RHB

Revisions to earnings forecasts

Our FY22F net profit is upgraded up by 10% with the MYR234.5m tax credit booked in 3QFY22 more than offset assumptions of higher allowance charges (mainly for O&G exposures) and additional tax for Cukai Makmur.

Figure 3: AMMB – revisions to earnings forecasts

FYE Mar (MYRm)	Previous FY22F	Previous FY23F	Previous FY24F	Revised FY22F	Revised FY23F	Revised FY24F	% Change FY22F	% Change FY23F	% Change FY24F
Net interest income	3,244	3,367	3,543	3,333	3,542	3,723	2.7%	5.2%	5.1%
Non-interest income	1,492	1,580	1,688	1,422	1,507	1,595	-4.7%	-4.6%	-5.5%
Operating expenses	(2,131)	(2,225)	(2,327)	(2,155)	(2,270)	(2,377)	1.1%	2.0%	2.1%
PIOP	2,606	2,722	2,905	2,600	2,779	2,941	-0.2%	2.1%	1.2%
Impairment charges	(728)	(495)	(465)	(861)	(561)	(516)	18.3%	13.4%	11.0%
Pretax profit	1,921	2,267	2,480	1,779	2,261	2,471	-7.4%	-0.3%	-0.4%
Net profit	1,276	1,638	1,764	1,404	1,662	1,808	10.1%	1.5%	2.5%
EPS (MYR)	0.19	0.24	0.26	0.43	0.50	0.55			
DPS (MYR)	-	0.19	0.21	-	0.19	0.21			
Loan growth (%)	4.1	5.5	5.0	5.3	5.2	5.0			
NIM (%)	2.03	2.05	2.06	2.02	2.03	2.03			
CIR (%)	45.0	45.0	44.5	45.3	45.0	44.7			
Credit cost (bps)	62	40	36	72	44	39			

Source: Company data, RHB

28 February 2022

Financial Services | Banks

Valuation and TP

Our new TP of MYR4.00 (from MYR3.90) is based on an intrinsic value of MYR4.08 and a 2% ESG discount based on RHB's in-house ESG methodology.


The intrinsic value is tweaked up, on a refresh of ROE and BVPS assumptions post the 3QFY22 results and earnings forecasts. The GGM-derived P/BV of 0.69x (from 0.67x) is slightly above -1SD from the historical mean.

Figure 4: AMMB – GGM valuation with ESG overlay

Cost of equity (COE) computation:		Sustainable ROE (%)	9.0
Risk free rate (%)	3.7	COE (%)	11.5
Equity premium (%)	7.1	Long-term growth (g)	3.5
Beta (x)	1.1	Implied P/BV (x)	0.69
Cost of equity - CAPM (%)	11.5	BVPS – 12-mth forward	MYR5.90
		Intrinsic value	MYR4.08
ESG premium/(discount) (%)	(2.0)	ESG premium/(discount)	(MYR0.08)
		TP (rounded)	MYR4.00


Source: Company data, RHB

Figure 5: AMMB's 12-month forward consensus P/E



Source: Bloomberg, RHB

Figure 6: AMMB's 12-month forward consensus P/BV



Source: Bloomberg, RHB

Recommendation Chart




Source: RHB, Bloomberg

Date	Recommendation	Target Price	Price
2021-11-28	Buy	3.90	3.15
2021-08-31	Buy	3.50	3.03
2021-06-01	Buy	3.30	2.86
2021-03-11	Buy	3.40	3.01
2021-03-01	Neutral	3.40	3.16
2020-12-16	Buy	4.20	3.66
2020-11-30	Buy	3.80	3.32
2020-06-29	Buy	3.70	3.08
2020-03-19	Neutral	3.30	2.93
2020-02-28	Neutral	4.00	3.70
2020-01-22	Neutral	4.20	3.82
2019-12-02	Neutral	4.30	3.94
2019-08-23	Neutral	4.45	4.13

Source: RHB, Bloomberg

ESG Rating History



Source: RHB

RHB Guide to Investment Ratings

Buy:	Share price may exceed 10% over the next 12 months
Trading Buy:	Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain
Neutral:	Share price may fall within the range of +/- 10% over the next 12 months
Take Profit:	Target price has been attained. Look to accumulate at lower levels
Sell:	Share price may fall by more than 10% over the next 12 months
Not Rated:	Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a

member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

Indonesia

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

Singapore

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S. broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

Malaysia

Save as disclosed in the following link [RHB Research conflict disclosures – Feb 2022](#) and to the best of our knowledge, RHBIB hereby declares that:

1. RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
2. RHBIB is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
3. None of RHBIB's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
**For the avoidance of doubt, the confirmation is only limited to the staff of research department*
4. RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
5. RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Thailand

Save as disclosed in the following link [RHB Research conflict disclosures – Feb 2022](#) and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:

1. RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
2. RHB Securities (Thailand) PCL is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
3. None of RHB Securities (Thailand) PCL's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
**For the avoidance of doubt, the confirmation is only limited to the staff of research department*
4. RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
5. RHB Securities (Thailand) PCL did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Indonesia

Save as disclosed in the following link [RHB Research conflict disclosures – Feb 2022](#) and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

1. PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report.
For the avoidance of doubt, interest in securities include the following:
 - a) Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the subject company's securities covered in this report*;
 - b) Being bound by an agreement to purchase securities or has the right to transfer the securities or has the right to pre subscribe the securities*.
 - c) Being bound or required to buy the remaining securities that are not subscribed/placed out pursuant to an Initial Public Offering*.
 - d) Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
2. PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
3. None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a director or board member* of the subject company(ies) covered in this report.
4. PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
5. PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

Notes:

**The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.*

***The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.*

Singapore

Save as disclosed in the following link [RHB Research conflict disclosures – Feb 2022](#) and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

1. RHB Bank Berhad, its subsidiaries and/or associated companies do not make a market in any issuer covered by the Singapore research analysts in this report.
2. RHB Bank Berhad, its subsidiaries and/or its associated companies and its analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered by the Singapore research analysts in this report.
3. RHB Bank Berhad's Singapore research staff or connected persons do not serve on the board or trustee positions of the issuer covered by the Singapore research analysts in this report.
4. RHB Bank Berhad, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
5. RHB Bank Berhad's Singapore research analysts, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report.
6. RHB Bank Berhad's Singapore research analysts do not receive any compensation or benefit in connection with the production of this research report or recommendation on the issuer covered by the Singapore research analysts.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that:

(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	-

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



KUALA LUMPUR

RHB Investment Bank Bhd
Level 3A, Tower One, RHB Centre
Jalan Tun Razak
Kuala Lumpur 50400
Malaysia
Tel : +603 9280 8888
Fax : +603 9200 2216

JAKARTA

PT RHB Sekuritas Indonesia
Revenue Tower, 11th Floor, District 8 - SCBD
Jl. Jendral Sudirman Kav 52-53
Jakarta 12190
Indonesia
Tel : +6221 509 39 888
Fax : +6221 509 39 777

BANGKOK

RHB Securities (Thailand) PCL
10th Floor, Sathorn Square Office Tower
98, North Sathorn Road, Silom
Bangrak, Bangkok 10500
Thailand
Tel: +66 2088 9999
Fax :+66 2088 9799

SINGAPORE

RHB Bank Berhad (Singapore branch)
90 Cecil Street
#04-00 RHB Bank Building
Singapore 069531
Fax: +65 6509 0470